Advances in B Cell Biology:
RA, SLE, and Vasculitis

 

This activity series has expired.
You will be redirected to the Rheumatology / Immunology specialty page.

 

Advances in B Cell Biology: RA, SLE, and Vasculitis is a series of CME-accredited series in which expert faculty bridge the gap between the complexities of current immunologic data and how they can be incorporated into clinical practice.

The increasing adoption of B cell-targeted therapies for autoimmune rheumatic diseases (ARDs) into clinical practice challenges clinicians to remain informed regarding data from new and ongoing research studies and clinical trials, especially those presented at national and international meetings. Designed for busy clinicians interested in keeping abreast of cutting-edge data and novel therapies in treatment of ARDs, the series provides information that can have significant positive impacts on patient outcomes.

Series Objectives

  1. Summarize recent findings on B cell biology as they apply to understanding the pathophysiology of autoimmune and inflammatory diseases and describe how this knowledge has influenced the development of new and innovative therapeutics utilizing these pathways.
  2. Describe recent clinical trial data on the efficacy and safety of biologic therapeutics targeting B cell pathways, including currently approved agents and those in development.
  3. Describe the role of B cells in the pathogenesis of SLE and assess data from recent clinical trials of novel therapeutics that target related pathways.
  4. Describe the role of B cells in the pathogenesis of systemic vasculitis and appraise recent clinical trial data on efficacy and toxicity of traditional and biologic therapies.

Target Audience

This activity is directed to rheumatologists, immunologists, allied health professionals, and other medical professionals, including nurse practitioners and physician assistants, who manage patients with rheumatic diseases.

Activity Director

Leonard H. Calabrese, DO
Professor of Medicine, Cleveland Clinic
Lerner College of Medicine of Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Orthopaedic & Rheumatologic Institute
Cleveland Clinic
Cleveland, OH